What has the Food and Drug Administration (FDA) announced recently in relation to Sporanox and Lamisil?
The FDA issued a Public Health Advisory to announce important safety-related updates to the labeling of Sporanox (itraconazole) and Lamisil (terbinafine hydrochloride) Tablets. FDA is advising healthcare professionals not to prescribe Sporanox to treat fungal infections (onychomycosis) in patients who have congestive heart failure (CHF) or a history of CHF. The updated Sporanox labeling also includes contraindications and precautions with certain medicines. FDA’s advisory also alerts the public that both Sporanox and Lamisil Tablets have been associated with serious liver problems including liver failure and death.
